Adjusted EBITDA is expected to be between $410 million and $440 million versus prior guidance of between $450 million and $490 million, due to expectations of lower pharmacy margins, cautious consumer demand and the related impact on seasonal markdowns and continued shrink expense. Retail pharmacy segment adjusted EBITDA is expected to be between $265 million and $285 million and pharmacy services segment adjusted EBITDA is expected to be between $145 million and $155 million. Adjusted net loss per share is expected to be between $2.18 and $1.78. Capital expenditures are expected to be approximately $225 million, with a focus on investments in digital capabilities, technology, prescription file purchases and distribution center automation. Rite Aid said it expects to generate positive free cash flow in fiscal 2023.